[Inhalation tobramycin for the management of cystic fibrosis]

Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Lopez A, Rey-Ares L, Alcaraz A, Bardach A, Ciapponi A, Spira C
Record ID 32014000264
Authors' objectives: To assess the available evidence on the efficacy, safety and comparative coverage related aspects among different inhalation tobramycin formulations in patients with cystic fibrosis.
Authors' recommendations: No studies comparing the differences between both Tobramycin inhalation solution presentations have been found. High quality evidence provided by one single comparative study of the two inhaled formulations did not find significant differences in clinically relevant results. It was found that Tobramycin inhalation powder has advantages in terms of administration and higher satisfaction for the patients although its use is associated to an increased use of other antibiotics and more side effects such as cough. In Argentina, the cost of the treatment implemented in this study is somewhat higher with Tobramycin inhalation powder than with Tobramycin inhalation solution.
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Administration, Inhalation
  • Cystic Fibrosis
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.